Zepsyre BRCA2 Patients . An Upcoming Conversation With An Expert - Discussing The BRCA Mutation Research Landscape: Lurbinectedin And Its Potential In BRCA2 Patients.

An Upcoming Conversation With An Expert - Discussing The BRCA Mutation Research Landscape: Lurbinectedin And Its Potential In BRCA2 Patients.

Jul. 18, 2017 8:16 AM

Wednesday 7-18, at 10:30am ET PharmaMar is Sponsoring an Expert Interview on Lurbinectedin and BRCA2 mutations with Slingshot Insights. With PharmaMar’s stock up over 45% in 2017 and multiple Phase 3 programs underway for Lurbinectedin, investor interest in the story has picked up this year.

This call will be an interview with Dr. Pamela Munster, a respected Oncologist and Key Opinion Leader. Dr. Munter is the Co-Director of the UCSF BRCA Research Center and Principal Investigator of many early oncology studies.

Why Investors Should Care:

Dr. Munster is a leading expert on BRCA research and involved in many early stage trials.

• The conversation will focus not just on PharmaMar’s Lurbinectedin, but DNA repair as a mechanism and where this approach could fit in a treatment landscape with approved PARP inhibitors.
• The call will examine the nuances of the public data for Lurbinectedin and give investors a deep dive into the basic science basis for the approach .

...